US › Healthcare

Allarity Therapeutics Inc (ALLR)

US · Healthcare · Biotechnology

$0.90+7.44%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-3.4M

EPS

$-0.21

EPS estimate

$-0.25

EPS came in at -0.21 against a street estimate of -0.25 — a beat of 16.0%.

Key statistics

Market cap

$13.7M

Forward P/E

0.0

P/B

4.63

Book value

$0.22

EPS (TTM)

$-0.79

52-week high

$1.84

52-week low

$0.77

50-day MA

$1.23

200-day MA

$1.23

Beta

0.57

Analyst view

Analysts rate Allarity Therapeutics Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $11.00.

Shareholding

Insiders

0.31%

Institutions

8.05%

Largest institutional holders

Fund	Stake
Renaissance Technologies Corp	2.08%
Vanguard Capital Management, LLC	1.08%
Geode Capital Management, LLC	0.97%
State Street Corp	0.86%
Militia Capital Management, LLC	0.62%
Citadel Advisors Llc	0.58%
Vanguard Fiduciary Trust Co	0.47%
HRT FINANCIAL LLC	0.23%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Allarity Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.